Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Verona Pharma Plc ADR (NASDAQ: VRNA) closed at $105.67 in the last session, up 0.05% from day before closing price of $105.62. In other words, the price has increased by $0.05 from its previous closing price. On the day, 2.34 million shares were traded. VRNA stock price reached its highest trading level at $105.7668 during the session, while it also had its lowest trading level at $105.57.
Ratios:
We take a closer look at VRNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.54 and its Current Ratio is at 10.71. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.87.
On July 01, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $170.
On April 28, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $100.TD Cowen initiated its Buy rating on April 28, 2025, with a $100 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 01 ’25 when Cunningham Kenneth sold 10,808 shares for $13.14 per share. The transaction valued at 142,057 led to the insider holds 79,776 shares of the business.
Deschamps Lisa sold 9,464 shares of VRNA for $124,392 on Aug 01 ’25. The Director now owns 84,856 shares after completing the transaction at $13.14 per share. On Aug 01 ’25, another insider, Fisher Andrew, who serves as the General Counsel of the company, sold 9,584 shares for $13.14 each. As a result, the insider received 125,969 and left with 417,903 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRNA now has a Market Capitalization of 8979720192 and an Enterprise Value of 72669732864. For the stock, the TTM Price-to-Sale (P/S) ratio is 40.77 while its Price-to-Book (P/B) ratio in mrq is 32.65. Its current Enterprise Value per Revenue stands at 327.824 whereas that against EBITDA is -1377.965.
Stock Price History:
The Beta on a monthly basis for VRNA is 0.14, which has changed by 2.926793 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, VRNA has reached a high of $105.85, while it has fallen to a 52-week low of $24.50. The 50-Day Moving Average of the stock is 4.11%, while the 200-Day Moving Average is calculated to be 52.67%.
Shares Statistics:
According to the various share statistics, VRNA traded on average about 3.49M shares per day over the past 3-months and 1460380 shares per day over the past 10 days. A total of 85.99M shares are outstanding, with a floating share count of 78.31M. Insiders hold about 8.93% of the company’s shares, while institutions hold 81.50% stake in the company. Shares short for VRNA as of 1755216000 were 2081728 with a Short Ratio of 0.71, compared to 1752537600 on 4059480. Therefore, it implies a Short% of Shares Outstanding of 2081728 and a Short% of Float of 2.5100000000000002.
Earnings Estimates
At present, 4.0 analysts are actively evaluating the performance of Verona Pharma Plc ADR (VRNA) in the stock market.The consensus estimate for the next quarter is $0.15, with high estimates of $0.38 and low estimates of -$0.09.
Analysts are recommending an EPS of between $0.29 and -$0.24 for the fiscal current year, implying an average EPS of $0.03. EPS for the following year is $2.24, with 4.0 analysts recommending between $3.61 and $1.04.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $86.72M. It ranges from a high estimate of $109.42M to a low estimate of $73.21M. As of the current estimate, Verona Pharma Plc ADR’s year-ago sales were $4.34MFor the next quarter, 8 analysts are estimating revenue of $94.61M. There is a high estimate of $111.83M for the next quarter, whereas the lowest estimate is $76.37M.
A total of 5 analysts have provided revenue estimates for VRNA’s current fiscal year. The highest revenue estimate was $323.84M, while the lowest revenue estimate was $279.76M, resulting in an average revenue estimate of $296.04M. In the same quarter a year ago, actual revenue was $33.49MBased on 10 analysts’ estimates, the company’s revenue will be $546.38M in the next fiscal year. The high estimate is $661.46M and the low estimate is $417.22M.
